Alembic Pharmaceuticals has achieved a significant regulatory milestone with final approval from the US Food and Drug Administration (USFDA) for its generic dapagliflozin tablets, a widely used treatment for Type 2 diabetes. The approval enables the company to market therapeutically equivalent versions of AstraZeneca’s Farxiga in the US, expanding its footprint in the high-value anti-diabetic segment. This development underscores Alembic’s strategic focus on complex generics and regulated markets.